$3.26
1.15% yesterday
Nasdaq, Dec 04, 10:00 pm CET
ISIN
US09071M1062
Symbol
BLRX

Bioline RX Ltd Sponsored ADR Stock price

$3.26
-0.04 1.30% 1M
-1.40 30.03% 6M
-5.30 61.95% YTD
-7.55 69.85% 1Y
-25.82 88.80% 3Y
-89.54 96.49% 5Y
-908.74 99.64% 10Y
-3,350.74 99.90% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.04 1.15%
ISIN
US09071M1062
Symbol
BLRX
Industry

Key metrics

Basic
Market capitalization
$13.7m
Enterprise Value
$-1.8m
Net debt
positive
Cash
$28.2m
Shares outstanding
2.6b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 7.0
EV/Sales
negative | 2.1
EV/FCF
0.1
P/B
0.7
Financial Health
Equity Ratio
34.6%
Return on Equity
-68.5%
ROCE
-52.2%
ROIC
-
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$17.3m | $2.6m
EBITDA
$-11.5m | $-10.4m
EBIT
$-14.5m | -
Net Income
$-7.8m | $-22.3m
Free Cash Flow
$-21.2m
Growth (TTM | estimate)
Revenue
1.2% | -91.1%
EBITDA
70.8% | 44.2%
EBIT
65.1% | -
Net Income
74.0% | -142.2%
Free Cash Flow
30.4%
Margin (TTM | estimate)
Gross
59.3%
EBITDA
-66.5% | -402.5%
EBIT
-84.1%
Net
-45.3% | -864.1%
Free Cash Flow
-122.9%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
4.4%
Employees
-
Rev per Employee
-
Show more

Is Bioline RX Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
1% 1%
100%
- Direct Costs 7.02 7.02
16% 16%
41%
10 10
7% 7%
59%
- Selling and Administrative Expenses 15 15
56% 56%
89%
- Research and Development Expense 8.38 8.38
21% 21%
49%
-11 -11
71% 71%
-66%
- Depreciation and Amortization 3.03 3.03
32% 32%
18%
EBIT (Operating Income) EBIT -15 -15
65% 65%
-84%
Net Profit -7.82 -7.82
74% 74%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about Bioline RX Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioline RX Ltd Sponsored ADR Stock News

Neutral
Seeking Alpha
10 days ago
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.
Neutral
PRNewsWire
10 days ago
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24 th, at 8:30 am EST - TEL AVIV, Israel , Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX...
Neutral
PRNewsWire
16 days ago
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.
More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office Israel
CEO Mr. Serlin
Founded 2003
Website www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today